Common Light Chain Antibody Mouse (CLC Mouse)
Common Light Chain Antibody Mouse (CLC Mouse) Overview
Bispecific antibodies are engineered antibodies capable of simultaneously binding to two antigens or epitopes, making them a focal point in antibody drug development. However, conventional monoclonal antibodies may encounter challenges with light and heavy chain mismatch when used in bispecific antibodies.
Our company has developed CLC mice, featuring a fixed light chain sequence. This innovative approach circumvents light and heavy chain mismatch issues right from the beginning. Additionally, the CLC mouse’s light chain boasts high solubility and stability. Its CDR region exhibits low immunogenicity and is easily humanized. This combination of features positions CLC mice as an ideal animal model for the development of bispecific antibodies.
All Antibody Discovery Services
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.